Phase 2 RCT: Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy.

Repeated intravenous cardiosphere-derived cell therapy in late-stage Duchenne muscular dystrophy (HOPE-2): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial – The Lancet

Commentary: Cellular therapy improves signs and symptoms of Duchenne muscular dystrophy – University of California – Davis Health

Commentary on Twitter

In patients with late-stage Duchenne muscular dystrophy, CAP-1002 cell therapy appears safe & effective in reducing deterioration of upper limb & cardiac function, trial suggests. Longer-term extension studies needed.

Explore full findings: https://t.co/bCLtsbuJH3 pic.twitter.com/h7vareAMC7

— The Lancet (@TheLancet) March 21, 2022